Skip to content

Resuscitation Quick Actions • First 2 Minutes

High-Acuity

Urinary Alkalinization

Sodium Bicarbonate 150 mEq in 1L D5W at 150–200 mL/hr; target urine pH 7.5–8.0 (effective ONLY for phenobarbital, pKa 7.2)

Multidose Charcoal (MDAC)

Activated Charcoal 50g initial, then 25g q2–4h; performs 'gastrointestinal dialysis' by binding phenobarbital in enterohepatic circulation

Coma Blisters (Bullae)

Tense clear/hemorrhagic bullae over bony pressure points; sterile dressing, avoid debridement

Barbiturate vs Benzo

Barbiturates can directly open GABA-A channels without GABA at high doses (no ceiling effect; can cause fatal asystole)

Hemodialysis Threshold

Level > 100 mcg/mL in acute phenobarbital, refractory hypotension, coma with respiratory failure, or renal impairment

Avoid Analeptics

Flumazenil is completely INEFFECTIVE against barbiturates; CNS stimulants are contraindicated

Bottom-Line Clinical Pearl

Barbiturates potentiate GABA-A signaling by increasing the DURATION of chloride channel opening (in contrast to benzodiazepines, which increase frequency). Overdose produces deep coma, respiratory arrest, hypothermia, hypotension, and pathognomonic cutaneous barbiturate bullae (tense non-erythematous blisters over pressure points). Short-acting barbiturates carry high mortality and cannot be eliminated by alkalinization. Long-acting phenobarbital is a weak acid (pKa 7.2) that can be cleared via urinary alkalinization (urine pH 7.5–8.0 with IV sodium bicarbonate) and Multidose Activated Charcoal (MDAC); severe poisonings with shock or renal failure require intermittent hemodialysis.

1. Cellular Mechanism: Barbiturates vs. Benzodiazepines

Barbiturates bind allosteric sites on the pentameric GABA-A receptor complex. While benzodiazepines increase the frequency of chloride channel opening and require endogenous GABA to function (creating a safety ceiling effect), barbiturates increase the duration of chloride channel opening. Furthermore, at elevated toxic concentrations, barbiturates can directly gate and open the chloride channel even in the complete absence of GABA, while simultaneously depressing excitatory AMPA/kainate glutamate receptors. This eliminates any pharmacodynamic ceiling effect, producing profound, life-threatening medullary cardiovascular and respiratory arrest.

2. Phenobarbital Clearance & Elimination Protocols

Elimination ModalityMechanism & AdministrationClinical Utility & Limitations
Urinary Alkalinization150 mEq Sodium Bicarbonate in 1L D5W titrated to urine pH 7.5 to 8.0Effective ONLY for phenobarbital (pKa 7.24). Alkalinizing urine ionizes phenobarbital into its impermeable conjugate base, preventing reabsorption in the proximal renal tubule. Completely ineffective for short-acting barbiturates (e.g., secobarbital, pentobarbital; pKa > 7.9).
Multidose Activated Charcoal (MDAC)Initial dose 50g orally or via NG tube, followed by 25g every 2 to 4 hoursEnhances non-renal elimination via gastrointestinal dialysis and interrupts enterohepatic circulation. Requires a secure airway (intubation) to prevent fatal charcoal pulmonary aspiration.
Intermittent HemodialysisVascular catheter access with high-efficiency dialyzerIndicated for serum phenobarbital concentrations > 100 mcg/mL, refractory shock, prolonged coma, or acute renal failure. Clears phenobarbital rapidly due to low molecular weight and moderate protein binding.
Board & Shelf Drill 5 Questions • Untimed Tutor Mode

Test Your Barbiturate Toxicity & Urinary Alkalinization Clinical Acumen

Directly launch an active-recall practice block from our 8,400+ validated COMLEX Level 1, 2-CE & 3 board question bank with complete explanations.